Prelude Therapeutics Inc
PRLD Nasdaq
SEC CIK 1678660
Follow Prelude Therapeutics
Weekly email: filings, results
Revenue, last quarter
$5.6M
−13.1% vs same quarter last year
Net income
−$12.5M
+36.4% vs same quarter last year
EPS, diluted
−$0.12
+53.8% vs same quarter last year
Operating cash flow
−$13.8M
+27.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$99.5M |
| FY24 | −$127.2M |
| FY23 | −$121.8M |
| FY22 | −$115.4M |
| FY21 | −$111.7M |
| FY20 | −$56.9M |
| FY19 | −$27.6M |
| FY18 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$56.4M |
| FY24 | −$103.7M |
| FY23 | −$110.6M |
| FY22 | −$86.7M |
| FY21 | −$85.9M |
| FY20 | −$46.8M |
| FY19 | −$26.4M |
| FY18 | - |